Zealand Pharma Shares Drop 3% Despite Positive Obesity Drug Trial Results

Key Facts

Zealand Pharma shares fell 3% despite announcing positive Phase 2 results for its obesity treatment. Investing.com reported that the stock price declined following the release of clinical trial data, which the company had characterized as successful.

The market reaction on October 8, 2026, suggests a potential 'sell the news' event or investor caution regarding the competitive landscape for weight-loss treatments. This volatility occurred against a broader economic backdrop where the European Union unemployment rate held steady at 6.4% on October 1, 2026.